Clinical Research Directory

Inclusion Criteria: * Male or female patients, regardless of race (residents in Greece), no younger than 18 years old at the initiation of treatment. * Patients with histologically or cytologically confirmed diagnosis of extensive Small Cell Lung Cancer (SCLC) * Patients who have not received prior systemic treatment for SCLC (chemotherapy or immunotherapy) * Patients for whom the decision to administer treatment with Durvalumab+chemotherapy has already been taken before their inclusion in the study and is clearly separated from the decision of the physician for the patient's participation in the current study. * Patients who have provided informed signed consent to participate in the study and to collect and analyze medical data related to the objectives of this study. Exclusion Criteria: * Patients with current diagnosis of primary cancer other than SCLC who require systemic or other treatment. * Patients who have previously received chemotherapy or immunotherapy for SCLC * Patients who are currently receiving or are expected to receive treatment with an investigational drug/medical device/intervention or who have received an investigational medicinal product within 1 month or 5 years half-life of the research agent (whichever is longer) before their initiation in this study.